BRCA1 and breast cancer: For BRCA1 heterozygotes, the HRs for association between the ER-negative PRS313 and contralateral breast cancer risk were similar for heterozygotes of pathogenic variants, which lead to a stable mutant protein (class II) compared with those leading to no protein or an unstable protein (class I).